ArticleRevista peruana de medicina experimental y salud publica2025
Adherence to colorectal cancer screening in a private health insurance center in Argentina from 2008 to 2022.
Article in Revista peruana de medicina experimental y salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation for the study. There is a need for information on population adherence to colon cancer screening. Main findings. Adherence to screening in health insurance increased to a maximum of 47.1% in December 2022, which is below desirable targets. The most commonly used method was colonoscopy. Public health implications. This information could contribute to the design of a multicomponent intervention to improve adherence to colon cancer screening. In order to evaluate adherence to colorectal cancer (CRC) screening among members of the Health Plan of the Hospital Italiano de Buenos Aires in Argentina, we conducted a retrospective cohort study using secondary data from the electronic medical record. We included all members over 50 years of age during the period 2008-2022. We assessed the number and type of screening tests performed and the proportion of members covered for screening. We analyzed 112,112 participants, with a median age of 58.6 years and a follow-up time of 8.6 years. Colonoscopy was the most commonly used test. The maximum coverage reached was 47.1% in December 2022. In conclusion, adherence to CRC screening was suboptimal, as was the method used. This information can be used for the design of a multicomponent intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.